SCHEMBL3450786

SCHEMBL3450786

CC(C)(C)CNc1nc(C#N)nc2ccc(OCc3cccnc3)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 5/20 0.49
CTSS P25774 4/20 0.49
CTSK P43235 1/20 0.49
GPR132 Q9UNW8 3/20 0.42
HTT P42858 2/20 0.41
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALK Q9UM73 1/20 0.40
CSF1R P07333 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450516 0.88 CTSL (0.41) CTSLCTSSCTSKCSF1RMAOA
SCHEMBL3451091 0.83 KCNA5 (0.43) CTSLCTSSCTSKHTTLMNA
SCHEMBL3449971 0.75 CCNE2 (0.42) CTSLCTSSCTSKKDM4EALDH1A1
SCHEMBL12933397 0.72 MAPK1 (0.50) GPR132MAPK1ALDH1A1GAAMEN1
SCHEMBL3450866 0.72 NSD2 (0.48) CTSK
SCHEMBL3451892 0.72 NSD2 (0.46) CTSLCTSSCTSKMEN1KMT2A
SCHEMBL3451605 0.70 NSD2 (0.51) MAOA
SCHEMBL492847 0.69 CSF1R (0.60) HTTMAPK1KDM4EALDH1A1GAA
SCHEMBL5434495 0.69 CTSS (0.47) CTSLCTSSCTSK
SCHEMBL3646807 0.68 MAOA (0.48) GPR132MAPK1ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
EP-1537111-B1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2007-05-02 EP disclosed
US-20060142575-A1 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2006-06-29 US disclosed
EP-1537111-A1 HETEREOARYL NITRILE DERIVATIVES Novartis AG (CH) 2005-06-08 EP disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES CTSK, CTSS, CTSZ CTSL 10/4885CTSS 2/4885CTSK 1/4885
US-20060142575-A1 Hetereoaryl nitrile derivatives CTSK, CTSZ, CTSE CTSL 12/4885CTSS 4/4885CTSK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.